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INTRODUCTION
Bladder cancer is a significant global health 
burden. It is the 10th most common cancer 
in the UK and worldwide, with the highest 
incidence rates in males and older people.1,2 
Bladder cancer is the ninth most common 
cause of cancer death in the UK1 and the 
15th worldwide.2 Early-stage diagnosis of 
cancer is associated with improved survival.3 
Identifying and understanding barriers to 
early-stage diagnosis of bladder cancer 
remain an important focus for research, 
clinical practice, and cancer policy. 
Sex disparities in bladder cancer diagnosis 
and outcomes are well documented. Although 
females have a lower bladder cancer 
incidence compared with males, overall they 
present with more advanced disease and a 
have worse survival rate.4–7 Of all the cancer 
types, bladder cancer has the largest sex 
difference in 1-year survival rate.3 Compared 
with males, females are approximately 
25% more likely to experience a delay in 
bladder cancer diagnosis of >9 months after 
presentation with haematuria.8 Additionally, 
females have ≥3 pre-referral consultations in 
primary care more often than males.9 
Multimorbidity, that is, the presence of 
≥2 concurrent medical conditions, may 
present a barrier to early-stage cancer 
diagnosis, including bladder cancer. 
Multimorbidity is highly prevalent in older 
people, who also have the highest incidence 
of bladder cancer.10 Multimorbidity has been 
associated with advanced-stage breast 
cancer diagnosis, acting through a number 
of mechanisms, including the competing-
demand and alternative-explanations 
hypotheses.11 In the competing-demands 
hypothesis, early symptoms of cancer may be 
overlooked by physicians or patients because 
the management of comorbid diseases 
diverts attention and resources away from 
the diagnosis of cancer. In the alternative-
explanations hypothesis, existing conditions 
that provide a plausible diagnostic alternative 
for the presenting cancer symptom may 
delay investigation and subsequent diagnosis 
of cancer. The role of multimorbidity, and 
the competing-demands and alternative-
explanations hypotheses in bladder cancer 
diagnosis remain poorly investigated. 
Further, most studies of the relationship 
between multimorbidity and cancer diagnosis 
examine the time to diagnosis rather than 
stage at diagnosis. The latter is more directly 
related to survival, so is preferable.
The aims of this study were: to assess 
whether having ≥1 comorbid conditions is 
associated with more advanced stage of 
bladder cancer at diagnosis; and test the 
‘alternative-explanations’ hypothesis,12 to see 
if it sheds light on the observed diagnostic 
delays experienced by females.
METHOD
Data source
This population-based, observational study 
was set in the Clinical Practice Research 
Datalink (CPRD) GOLD database with linkage 
Abstract
Background
Pre-existing concurrent medical conditions 
(multimorbidity) complicate cancer diagnosis 
when they provide plausible diagnostic 
alternatives for cancer symptoms. 
Aim
To investigate associations in bladder cancer 
between: first, pre-existing condition count 
and advanced-stage diagnosis; and, second, 
comorbidities that share symptoms with bladder 
cancer and advanced-stage diagnosis.
Design and setting
This observational UK cohort study was set in the 
Clinical Practice Research Datalink with Public 
Health England National Cancer Registration and 
Analysis Service linkage. 
Method
Included participants were aged ≥40 years 
with an incident diagnosis of bladder cancer 
between 1 January 2000 and 31 December 
2015, and primary care records of attendance 
for haematuria, dysuria, or abdominal mass in 
the year before diagnosis. Stage at diagnosis 
(stage 1 or 2 versus stage 3 or 4) was the outcome 
variable. Putative explanatory variables using 
logistic regression were examined, including 
patient-level count of pre-existing conditions and 
‘alternative-explanations’, indicating whether 
pre-existing condition(s) were plausible diagnostic 
alternatives for the index cancer symptom. 
Results
In total, 1468 patients (76.4% male) were studied, 
of which 399 (35.6%) males and 217 (62.5%) 
females had alternative explanations for their 
index cancer symptom, the most common being 
urinary tract infection with haematuria. Females 
were more likely than males to be diagnosed with 
advanced-stage cancer (adjusted odds ratio [aOR] 
1.62; 95% confidence interval [CI] = 1.20 to 2.18; 
P = 0.001). Alternative explanations were strongly 
associated with advanced-stage diagnosis in both 
sexes (aOR 1.69; 95% CI = 1.20 to 2.39; P = 0.003).
Conclusion
Alternative explanations were associated with 
advanced-stage diagnosis of bladder cancer. 
Females were more likely than males to be 
diagnosed with advanced-stage disease, but 
the effect was not driven entirely by alternative 
explanations.
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to Public Health England National Cancer 
Registration and Analysis Service (NCRAS, 
Set 15) and Office for National Statistics 
data. NCRAS collects detailed information 
on >99% of all non-skin cancer tumours in 
England. Set 15 includes cancers diagnosed 
between January 1990 and December 2015, 
coded using the International Classification 
of Diseases, 10th revision (ICD-10).13 
The CPRD is the largest database of 
anonymised, longitudinal electronic medical 
records from primary care in the world.14 
CPRD GOLD contains data collected as part 
of routine clinical care in general practices 
in the UK. In 2013, data linkage between 
the CPRD and NCRAS was enabled for 404 
practices, representing approximately 75% 
of English practices and 58% of UK practices 
in the CPRD.
Patient inclusion criteria
Patient inclusion criteria were as follows:
• an incident bladder cancer code (any 
ICD-10 code commencing C67, denoting 
malignant neoplasm of the bladder) 
in NCRAS between 1 January 2000 
and 31 December 2015, with stage at 
diagnosis; 
• a minimum of 1 year of CPRD records, 
containing ≥1 consultations preceding the 
cancer diagnosis and presenting with ≥1 
possible symptoms of bladder cancer, 
using National Institute for Health and 
Care Excellence (NICE) guidelines.15,16 
GPs have no opportunity to be involved 
in patients’ cancer diagnosis if the patient 
does not consult or is asymptomatic; and,
• aged ≥40 years on diagnosis.
Bladder cancer symptoms
Four symptoms of bladder cancer were 
selected: haematuria (visible or non-visible), 
dysuria, and abdominal mass.15,16 Libraries 
of Read codes that might be used by GPs to 
record these symptoms were collated using 
robust methods.17 Symptomatic patients 
were identified by the presence of any of 
these codes in their records. Symptoms 
presented >1 year before diagnosis are 
not reliably more common in people who 
are subsequently diagnosed with cancer 
compared with controls; therefore, searches 
were constrained to 1 year before diagnosis.18 
The earliest recorded symptom(s) of bladder 
cancer was identified, and denoted the index 
date. 
Comorbidity
The authors identified whether patients 
had comorbid medical conditions before 
their index date. The choice of conditions 
was made by two medical students in 
the research group and one experienced 
GP from the group. Criteria for condition 
selection included reliability of recording or 
sharing symptoms with bladder cancer:
• conditions that are part of the Quality and 
Outcomes Framework (QOF), the pay-for-
performance scheme in the UK.19 QOF 
conditions are well defined, and, being 
linked to practice payments, recording 
is likely to be good. The following QOF 
conditions were selected: asthma, atrial 
fibrillation, chronic obstructive pulmonary 
disease, coronary heart disease, 
dementia, depression, diabetes mellitus, 
epilepsy, heart failure, hypertension, 
and stroke. Anxiety was also included 
because it has been linked to increased 
time to cancer diagnosis in previous work; 
and,12,20 
• conditions that share the following 
symptoms with bladder cancer: 
 — haematuria and dysuria: urinary tract 
infection, sexually transmitted disease, 
kidney disease, urinary tuberculosis, 
sickle cell disease, nephrolithiasis, 
prostatitis, menorrhagia (presumably 
misattributed haematuria), 
endometriosis, and benign prostatic 
How this fits in 
Early-stage diagnosis of cancer is associated 
with improved outcomes, including 
survival. The impact of multimorbidity on 
the diagnostic process in symptomatic 
patients, and on the likelihood of early-stage 
diagnosis, is poorly understood. This research 
investigated if the condition count and the 
presence of conditions that share symptoms 
with bladder cancer are associated with 
advanced-stage bladder cancer diagnosis. 
The findings confirm that females are 
more likely than males to be diagnosed 
with advanced-stage bladder cancer. To the 
authors’ knowledge, this study is the first to 
show that pre-existing conditions providing 
plausible diagnostic alternatives for bladder 
cancer symptoms (notably urinary tract 
infections) are associated with advanced-
stage bladder cancer diagnosis. Alternative 
explanations do not account for the poorer 
outcomes for females compared with males. 
In line with the 2015 National Institute for 
Health and Care Excellence suspected 
cancer referral guidelines, it is recommended 
that clinicians consider undiagnosed bladder 
cancer in patients aged ≥40 years with visible 
haematuria, dysuria, abdominal mass, or 
urinary tract infection.
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hyperplasia; and,
 — abdominal mass: uterine fibroids, aortic 
aneurysm, and retention.
Libraries of Read codes for the above 
conditions were collated,17 and patients with 
these conditions were identified. 
Two patient-level variables were created: 
the patient’s pre-existing conditions count; 
and the ‘alternative-explanations’ variable, 
identifying whether the patient had a history 
of a comorbid condition that could provide 
an alternative explanation for their index 
symptom of bladder cancer. 
Stage at diagnosis
Stage at diagnosis was provided by NCRAS. 
Stage was categorised as ‘early’ (stages 1 
or 2) or ‘advanced’ (stages 3 or 4) for the 
regression analyses. 
Patient characteristics
Patient sex was obtained from the patient 
file provided by CPRD GOLD. Patient age 
at diagnosis was estimated, assuming that 
the patient was born on 1 July of their year 
of birth, provided by CPRD GOLD. Patient-
level deprivation was estimated using the 
Townsend Score as a quintile score of 1 
(least deprived) to 5 (most deprived) by 
linked Office for National Statistics data.
Data analysis
Simple descriptive statistics were used for 
demographic data. Associations between 
stage of cancer at diagnosis, ordinal 
condition count, and binary ‘alternative-
explanations’ variables were analysed 
using logistic regression. The analyses 
were adjusted for age at diagnosis, sex, and 
deprivation. Interaction terms were sought 
on clinical grounds between sex and: count 
of pre-existing conditions; and presence of 
an alternative explanation. Post-estimation 
diagnostics tested for model specification 
(linktest), goodness of fit (lfit), and collinearity 
between explanatory variables (collin). All 
analyses used Stata/SE (version 16).
Missing data
Both the CPRD and NCRAS have some 
missing data. Data may be missing in the 
CPRD because they were not reported by 
the patient, or not recorded by the GP using 
a Read code. In line with standard practice, 
the absence of a Read code for a symptom 
was interpreted as an absence of the 
symptom itself.14 The authors acknowledge 
from previous experience that this is likely to 
result in an underestimation of people with 
symptoms of bladder cancer.21 
NCRAS introduced a change in reporting 
standards in 2012 affecting the consistency 
of data collection and quality across the 
study period. Logistic regression was used to 
check for any associations between ‘missing 
stage’ and the explanatory variables.
Power calculation
A sample of 1468 people has 99% power 
to detect a 10-point increase in percentage 
of advanced-stage diagnoses in the group 
with alternative explanations for their first 
symptom of cancer compared with those 
without, that is, a change from 20% to 
30%. This was based on 42% of the sample 
having an alternative explanation for their 
cancer symptom12 and a baseline of 20% 
of patients being diagnosed with advanced-
stage disease.1
Sensitivity analyses
Urinary tract infection, although an 
alternative explanation for haematuria and 
dysuria, is also listed in the NICE suspected 
cancer referral guidelines as a possible 
feature of undiagnosed bladder cancer 
warranting investigation.15 Two sensitivity 
analyses were carried out, with results 
reported in Supplementary Tables S2 
and S3. First, separate effects of alternative 
explanations for bladder cancer symptoms 
were sought between those with and 
without urinary tract infection. The second 
sensitivity analysis excluded participants 
who presented with urinary tract infection 




The CPRD and NCRAS searches identified 
3575 adults (n = 2606 males, n = 969 females) 
diagnosed with bladder cancer between 
1 January 2000 and 31 December 2015. 
Of these, 2107 were excluded from the 
analyses for the reasons given in Figure 1. 
The distribution of participants by year of 
diagnosis varied, rising from 184 (12.5%) 
in 2000–2003, peaking in 2008–2011 (520, 
35.4%), and reducing to 386 (26.3%) in 
2012–2015. Levels of missing staging data 
reduced considerably over time (Table 1). 
The final analyses included 1468 
(n = 1121 males, n = 347 females) 
symptomatic adults aged ≥40 years 
with known stage of bladder cancer. The 
mean age at diagnosis was 72.9 years 
(95% confidence interval [CI] = 72.4 to 73.5) 
and 74.7 years (95% CI = 73.6 to 75.8) for 
males and females, respectively. Patient 
characteristics by cancer stage are shown 
in Table 1.
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Index symptoms of cancer
The majority of patients (n = 1459/1468, 
99.4%) had a single index symptom of 
bladder cancer recorded in the year before 
diagnosis. The most common bladder 
cancer symptom was visible haematuria 
(n = 954/1121, 85.1% of males; n = 275/347, 
79.3% of females), followed by dysuria 
(n = 120/1121, 10.7% of males; n = 57/347, 
16.4% of females). Index symptoms of non-
visible haematuria (n = 44/1121, 3.9% of 
males; n = 11/347, 3.2% of females) and 
abdominal mass (n = 3/1121, 0.3% of males; 
n = 4/347, 1.2% of females) were infrequent. 
The nine patients with two index symptoms 
of bladder cancer had haematuria and 
dysuria (data not shown). 
Comorbid conditions
The majority (n = 1178/1468, 80.2%) 
of patients had been diagnosed with ≥1 
comorbid condition before their index 
symptom of bladder cancer (Table 1). Of the 
QOF conditions (Table 2), by far the most 
common in both sexes was hypertension 
(n = 451/1121, 40.2% of males; n = 166/347, 
47.8% of females). Depression and/or anxiety 
was more common in females (n = 115/347, 
33.1%) than in males (n = 205/1121, 
18.3%). The comorbid conditions provided 
alternative explanations for the first possible 
symptom of bladder cancer for 616 of 1468 
(42.0%) patients overall (Table 1). This was 
more likely for females (n = 217/347, 62.5%) 
than for males (n = 399/1121, 35.6%) (data 
not shown). Of the conditions that presented 
with haematuria and dysuria, the most 
common was urinary tract infection, which 
was diagnosed in a greater proportion of 
females (n = 170/347, 49.0%) than in males 
(n = 193/1121, 17.2%). A small proportion 
(n = 98/1468, 6.7%) of patients had conditions 
presenting with abdominal mass (Table 2). 
Some of the comorbid conditions sharing 
symptoms with bladder cancer were sex-
specific; namely, conditions of the prostate 
are only experienced by males, whereas 
menorrhagia, endometriosis, and uterine 
fibroids are specific to females. Similar 
proportions of males (n = 160/1121, 14.3%) 
and females (n = 58/347, 16.7%) had sex-
specific comorbidities. 
Stage at diagnosis
Bladder cancer was diagnosed at an early 
stage in 1199 of the 1468 patients (81.7%) and 
at an advanced stage in the remaining 269 
(18.3%), with no gross fluctuation over time 
(Table 1). A greater proportion of females 
experienced advanced-stage (n = 87/347, 
25.1%) than early-stage (n = 260/347, 74.9%) 
disease. The proportion of people with ≥1 
comorbid condition was similar in the groups 
with early-stage (n = 960/1199, 80.1%) and 
with advanced-stage (n = 218/269, 81.0%) 
disease. The proportion of people with 
an alternative explanation for their index 
bladder cancer symptom was higher in 
the group diagnosed with advanced-stage 
cancer (n = 134/269, 49.8%) than in those 
with early-stage disease (n = 482/1199, 
40.2%) (Table 1).
Table 1. Patient characteristics
 Early-stage Advanced-stage Overall Stage missing 
Covariate cancer (N = 1199) cancer (N = 269) (N = 1468) (N = 745)
Age, years, mean (SD) 73.7 (10.1) 71.7 (10.1) 73.3 (10.1) 72.9 (11.1)
Sex, female, n (%) 260 (21.7) 87 (32.3) 347 (23.6) 189 (25.4)
Townsend quintile, mean (SD) 2.7 (1.3) 2.6 (1.3) 2.7 (1.3) 2.8 (1.3)
Number of conditions, n
 0 239 51 290 167
 1 292 73 365 202
 2 257 58 315 170
 3 200 40 240 98
 ≥4 211 47 258 108
Alternative explanation, n (%) 482 (40.2) 134 (49.8) 616 (42.0) 275 (36.9)
Participants in each study period, n (%)
 2000–2003  156 (84.8)a 28 (15.2)a 184 (12.5)b 230 (30.9)b
 2004–2007 322 (85.2)a 56 (14.8)a 378 (25.7)b 316 (42.4)b
 2008–2011 417 (80.2)a 103 (19.8)a 520 (35.4)b  168 (22.6)b 
 2012–2015 304 (78.8)a 82 (21.2)a 386 (26.3)b 31 (4.2)b
 Total 1199 (81.7)a 269 (18.3)a 1468 (100)b 745 (100)b
aPercentage calculated from total participants each study period. bPercentage calculated from total number of 
symptomatic participants of entire study aged ≥40 years. SD = standard deviation.
Figure 1. Application of exclusion criteria. 










Excluded (n = 1)
for missing Townsend data
Patients in final analyses
N = 1468
Excluded (n = 8)
for age <40 years
Excluded (n = 1234)
for missing stage
Excluded (n = 864)
for no recorded symptom/
no GP attendance
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Regression analyses
Females were more likely to be diagnosed 
with advanced-stage cancer than 
males (adjusted odds ratio [aOR] 1.62; 
95% CI = 1.20 to 2.18; P = 0.001) (Table 3). 
Alternative explanations for the first 
possible symptom of bladder cancer were 
strongly associated with advanced-stage 
diagnosis (aOR 1.69; 95% CI = 1.20 to 2.39; 
P = 0.003). 
The interaction term between sex and 
alternative explanations was not statistically 
significant (see Supplementary Table S1). 
Post-estimation regression diagnostics 
suggested no problems of model 
specification, goodness of fit, or collinearity 
between explanatory variables.
A logistic regression analysis comparing 
patients with and without complete staging 
information indicated that missingness 
was random with regard to all explanatory 
variables. 
Sensitivity analyses
Only alternative explanations provided by 
urinary tract infections (n = 363/616, 58.9%) 
were strongly associated with advanced-
stage diagnosis (aOR 2.02; 95% CI = 1.39 
to 2.94; P<0.0001) (see Supplementary 
Table S2). 
Associations with advanced-stage 
diagnosis for sex (aOR 1.37; 95% CI = 0.98 to 
1.93; P = 0.068) and alternative explanations 
(aOR 1.43; 95% CI = 0.98 to 2.08; P = 0.062) 
were weakened when the authors excluded 
the 132 of 363 (36.4%) urinary tract 
infections occurring in the 6 months before 
participants were diagnosed with bladder 
cancer (see Supplementary Table S3).
DISCUSSION
Summary
Having comorbid conditions that offered 
plausible diagnostic alternatives for the 
symptoms of bladder cancer increased the 
odds of being diagnosed with advanced-
stage disease (aOR 1.69; 95% CI = 1.20 to 
2.39; P = 0.003). 
This effect was the same in males and 
females, and is unlikely to account for the 
observation that females are more likely 
than males to be diagnosed with advanced-
stage bladder cancer (aOR 1.62; 95% 
CI = 1.20 to 2.18; P = 0.001). 
Sensitivity analysis indicated that the 
effect of alternative explanations was 
carried by urinary tract infections, which 
are a classical alternative explanation when 
bladder cancer is present. Some of these 
may be misdiagnoses, and others true 
urinary tract infections as a complication 
of the cancer. 
The sensitivity analyses of removing 
patients whose urinary tract infections 
only occurred in the final 6 months before 
diagnosis suggests that this pattern exists 
and that it has consequences for some of 
these patients (mostly females), who have a 
worse stage at diagnosis as a result.
Table 3. Association between stage of bladder cancer diagnosis, 
multimorbidity, and alternative explanations for cancer symptoms; 
adjusted for age, sex, and deprivation
 Unadjusted Adjusted
Covariate OR (95% CI) P-value OR (95% CI) P-value
Age at diagnosis 0.98 (0.97 to 0.99) 0.003 0.98 (0.97 to 0.99) 0.002
Female sex 1.73 (1.29 to 2.31) <0.0001 1.62 (1.20 to 2.18) 0.001
Deprivation quintile 0.96 (0.86 to 1.10) 0.369 0.95 (0.86 to 1.05) 0.337
Number of comorbidities (ref: none)
 1 1.17 (0.79 to 1.74) 0.434 1.01 (0.66 to 1.52) 0.980
 2 1.06 (0.70 to 1.60) 0.792 0.84 (0.53 to 1.33) 0.450
 3 0.94 (0.59 to 1.48) 0.780 0.72 (0.42 to 1.24) 0.242
 ≥4 1.04 (0.67 to 1.62) 0.848 0.75 (0.43 to 1.30) 0.303
Has an ‘alternative explanation’ 1.48 (1.13 to 1.92) 0.004 1.69 (1.20 to 2.39) 0.003
OR = odds ratio.
Table 2. Comorbid conditions diagnosed before the first possible 
symptom of bladder cancer
Classification  Males, n (%)  Females, n (%)  Total, n (%)  
of condition Condition (N = 1121) (N = 347) (N = 1468)
QOF Asthma  107 (9.5) 40 (11.5) 147 (10.0)
 Atrial fibrillation 78 (7.0) 20 (5.8) 98 (6.7)
 Chronic obstructive 117 (10.4) 22 (6.3) 139 (9.5) 
  pulmonary disease
 Coronary heart disease 225 (20.1) 48 (13.8) 273 (18.6)
 Dementia  21 (1.9) 3 (0.9) 24 (1.6)
 Depression and/or anxiety 205 (18.3) 115 (33.1) 320 (21.8)
 Diabetes mellitus 159 (14.2) 37 (10.7) 196 (13.4)
 Epilepsy  15 (1.3) 8 (2.3) 23 (1.6)
 Heart failure 49 (4.4) 24 (6.9) 73 (5.0)
 Hypertension  451 (40.2) 166 (47.8) 617 (42.0)
 Stroke  97 (8.7) 30 (8.6) 127 (8.7)
Presents with Urinary tract infection 193 (17.2) 170 (49.0) 363 (24.7)
haematuria Sexually transmitted disease 2 (0.2) 1 (0.3) 3 (0.2)
and dysuria Kidney disease 135 (12.0) 51 (14.7) 186 (12.7)
 Tuberculosis  5 (0.4) 3 (0.9) 8 (0.5)
 Sickle cell disease 0 0 0
 Nephrolithiasis  24 (2.1) 3 (0.9) 27 (1.8)
 Prostatitis  140 (12.5) 0 140 (9.5)
 Menorrhagia  0 54 (15.6) 54 (3.7)
 Endometriosis  0 3 (0.9) 3 (0.2)
 Benign prostatic hyperplasia 20 (1.8) 0 20 (1.4)
 Pyelonephritis 2 (0.2) 7 (2.0) 9 (0.6)
Presents with Uterine fibroids 0 1 (0.3) 1 (0.1)
abdominal Aortic aneurysm 46 (4.1) 3 (0.9) 49 (3.3)
mass Retention  35 (3.1) 15 (4.3) 50 (3.4)
QOF = Quality and Outcomes Framework. 
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Strengths and limitations
A real strength of this study was its setting 
in primary care, where GPs face the difficult 
clinical problem of recognising possible 
cancer symptoms but which could be 
plausibly explained by a patient’s existing 
medical conditions. The CPRD is the largest 
database of longitudinal primary care 
records in the world and is recognised for 
its high-quality data.14 Robust methods for 
case identification in the CPRD were used17 
and cancer diagnoses were validated by 
NCRAS.
Despite this, the use of CPRD and 
NCRAS data has some limitations. Primary 
care doctors may record information in 
free-text fields, which are not included in 
CPRD research data.22 Based on previous 
studies of data loss in text fields, the 
authors anticipated that they identified 80% 
of the true numbers of people with visible 
haematuria.21,23 
Further limitations included the amount 
of missing staging data: of the present 
original sample of 3575 patients, 1234 
(34.5%) were missing staging data and so 
were excluded from the analyses. Stage 
completeness improved dramatically in 
2011–2015, so it could not be assumed 
that staging data before this were missing 
at random. The authors had considered 
restricting the sample to 2011–2015, but 
the sample number would have been too 
low (n = 368), partly because of the reducing 
size of the CPRD in this period (Price et al, 
unpublished data, 2020). It was reassuring 
that there was no evidence of an association 
between missing staging data and any of 
the explanatory variables in the analyses. 
Comparison with existing literature
To the authors’ knowledge, this is the first 
study to investigate the impact of comorbid 
conditions that provide a plausible 
explanation for the symptoms of bladder 
cancer on stage of diagnosis. 
The present findings are consistent 
with Gurney and colleagues' study, which 
reported that increasing comorbidity 
index was not associated with increased 
odds of late-stage diagnosis of urological 
cancers.24 These authors did not explore the 
alternative-explanations hypothesis.
The findings presented here further 
confirm an evidence synthesis of seven 
studies reporting that females are more 
likely than males to have advanced tumours 
at the time of diagnosis,4 and are at greater 
risk of emergency presentation.25 Possible 
explanations for the poorer outcomes in 
females include the observed delay in their 
referral and poor recognition of their urinary 
symptoms.7,9 The authors deliberately 
sought, but did not find, any evidence that 
the presence of alternative explanations for 
the index bladder cancer symptom might 
account for the poorer outcomes in females 
than males.
The sensitivity analyses findings are 
consistent with the possibility that patients 
who present with urinary tract infection 
have a particularly aggressive type of 
bladder cancer; hence, the association with 
advanced-stage diagnosis. The prognosis 
for bladder cancer is known to be worse 
for patients who do not present with alarm 
symptoms, compared with those who 
do.26 In the present study, the alternative 
explanations were paired between urinary 
tract infection and the alarm symptom, 
haematuria. Therefore, the authors consider 
their findings more likely to represent 
the scenario of delayed investigation for 
possible cancer where plausible diagnostic 
alternatives for the symptoms of cancer 
exist.9 
Implications for research and practice
The present findings suggest that the 
presence of conditions that provide plausible 
diagnostic alternatives for bladder cancer 
symptoms are associated with diagnostic 
delay, and increase the risk of advanced-
stage disease, in males and in females. It is 
important to note that this is an association, 
not evidence of misdiagnosis. 
In line with the 2015 NICE suspected 
cancer referral guidelines, the authors 
recommend that clinicians retain the 
possibility of undiagnosed bladder cancer 
in patients aged ≥40 years with visible 
haematuria, dysuria, or abdominal mass. 
Studies could investigate the optimal period 
of 'watchful waiting' for morbid patients 
with haematuria and urinary tract infection 
that minimises the risk of advanced-stage 
bladder cancer diagnosis. Furthermore, 
if associations with non-investigation of 
possible bladder cancer despite symptoms 
can be identified, then interventions to help 
reduce advanced-stage diagnosis can be 
designed and tested. 
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